Convergen Raises $15M Seed to Advance Neurodegeneration Therapeutics

Convergen Secures $15M Seed Funding

Convergen, a biotech company focused on neurodegeneration and related fields, has raised $15 million in a Seed round. The investment was led by MPCi, with participation from LAV and BioTrack Capital.

Company Focus

Convergen is developing innovative therapeutic platforms, including its proprietary TrimTAC technology, aimed at addressing challenging diseases in neurodegeneration. The company's work is positioned at the forefront of biotech innovation in this space.

Funding Details

The Seed round, announced on August 31, 2026, brings total early-stage capital to support Convergen's research and development efforts. The lead investor, MPCi, along with other backers, will provide strategic guidance as the company advances its pipeline.

Implications

This funding will enable Convergen to accelerate its preclinical programs and expand its platform capabilities. The company's focus on neurodegeneration represents a critical area of unmet medical need, and this investment underscores growing interest in novel therapeutic approaches.

Convergen's progress will be closely watched as it moves toward clinical development. The backing from experienced investors like MPCi, LAV, and BioTrack Capital signals confidence in the company's scientific approach and potential impact.